false
Catalog
2023 World Conference on Lung Cancer (Posters)
EP12.02. Comparative Efficacy and Safety of Lorlat ...
EP12.02. Comparative Efficacy and Safety of Lorlatinib vs Alectinib and Brigatinib Using Matching Adjusted Indirect Comparisons (MAIC) - PDF(Abstract)
Back to course
Pdf Summary
This study compared the efficacy and safety of lorlatinib, alectinib, and brigatinib, which are all next generation anaplastic lymphoma kinase (ALK) inhibitors, in the treatment of advanced non-small cell lung cancer (aNSCLC). The authors conducted a literature review to identify relevant trials and compared their design, outcome definitions, and baseline characteristics. They used the anchored Matching Adjusted Indirect Comparison (MAIC) approach to account for imbalances in effect modifiers and propensity scores to match baseline characteristics. The results showed that lorlatinib demonstrated superior progression-free survival (PFS) compared to alectinib in global patients and brigatinib in global patients, and similar PFS compared to alectinib in Asian patients. Objective response rates were similar between lorlatinib and brigatinib, but no data was reported for alectinib. The risks of adverse events leading to treatment discontinuation, interruption, and dose reduction were similar for all three ALK inhibitors. However, lorlatinib was associated with a higher risk of grade 3 adverse events compared to alectinib but not compared to brigatinib. In conclusion, this study supports the use of lorlatinib as a first-line treatment for ALK-positive aNSCLC based on its superior efficacy compared to alectinib and brigatinib, with similar safety profiles among the three inhibitors.
Asset Subtitle
Christine Garcia
Meta Tag
Speaker
Christine Garcia
Topic
Metastatic NSCLC: Targeted Therapy - FUSIONS
Keywords
lorlatinib
alectinib
brigatinib
ALK inhibitors
non-small cell lung cancer
advanced NSCLC
efficacy
safety
progression-free survival
objective response rates
×
Please select your language
1
English